XERS · Xeris Biopharma Holdings, Inc. · Webcasts, Transcripts & Audio
$10.02
-0.11 (-1.09%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$1.66B
Shares
182.32M
Volume · Oct 6
2.4M
Avg daily vol (3M)
2.2M
Xeris Biopharma Holdings, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Xeris Biopharma Holdings, Inc. (XERS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲168.8%
$29.73M
−$21.83M
'22 Q3
22-11-09
▲54.7%
$33.14M
−$12.93M
'22 Q4
23-01-05
▲50.4%
$33.20M
−$16.83M
'23 Q1
23-05-09
▲50.2%
$38.01M
−$19.84M
'23 Q2
23-08-08
▲62.6%
$48.32M
−$12.19M
'23 Q3
23-11-09
▲33.9%
$44.39M
−$13.39M
'23 Q4
24-03-06
▲22.4%
$40.64M
−$18.98M
'24 Q1
24-05-09
▲26.5%
$48.06M
−$15.01M
'24 Q2
24-08-08
▲12.3%
$54.27M
−$15.74M
'24 Q3
24-11-08
▲35.4%
$60.10M
−$5.11M
'24 Q4
25-01-10
▲47.9%
$60.12M
−$9.22M
'25 Q1
25-05-08
▲48.8%
$71.54M
−$1.93M
'25 Q2
25-08-07
▲37.1%
$74.38M
$621,000
'25 Q3
25-11-06
▲42.8%
$85.81M
$11.08M
'25 Q4
26-03-02
▲38.3%
$83.13M
$2.23M
'26 Q1
26-05-07
LATEST
▲28.7%
$92.10M
−$31.10M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Confident tone
ReCorelev commercial growth
Intellectual property portfolio expansion
Kevegis (Coveus) brand and IP protection
Revenue
$92.10M
▲ 28.7% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Confident tone
Recorlev growth and commercial expansion
Gvoke Medicare headwinds and recovery
Financial discipline and capital allocation
Revenue
$83.13M
▲ 38.3% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Confident tone
Recorlev growth and commercial expansion
XP-8121 Phase III pipeline
2026 revenue guidance and R&D investment
Revenue
$85.81M*
▲ 42.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Confident tone
RECORLEV growth and franchise
Pipeline: XP-8121 (levothyroxine)
Financial performance and profitability
Revenue
$74.38M
▲ 37.1% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Confident tone
Recorlev growth and Cushing's/hypercortisolism market
Gvoke performance and growth runway
XP-8121 pipeline asset for hypothyroidism
Revenue
$71.54M
▲ 48.8% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Confident tone
Gvoke performance
XP-8121 pipeline and investor day
Recorlev growth and commercial momentum
Revenue
$60.12M
▲ 47.9% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript
Confident tone
Recorlev growth
2025 financial guidance
Gvoke commercial performance
Revenue
$60.10M*
▲ 35.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript
Confident tone
Recorlev commercial growth
Gvoke performance and share gains
Keveyis durability against generics
Revenue
$54.27M
▲ 12.3% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
Confident tone
Recorlev performance in Cushing's syndrome
Gvoke glucagon franchise
Keveyis franchise resilience post-orphan exclusivity
Revenue
$48.06M
▲ 26.5% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript
Confident tone
Total revenue growth and raised guidance
Gvoke and Change Healthcare cyber breach impact
Severe hypoglycemia and co-prescribing of rescue therapy
Revenue
$40.64M
▲ 22.4% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Xeris Biopharma Holdings, Inc. (XERS) Q4 2023 Earnings Call Transcript
Confident tone
Recorlev Cushing's syndrome
Gvoke glucagon franchise
Keveyis and generic competition
Revenue
$44.39M*
▲ 33.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Call Transcript
Revenue
$48.32M
▲ 62.6% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript
Revenue
$38.01M
▲ 50.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Call Transcript
Revenue
$33.20M
▲ 50.4% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Xeris Biopharma Holdings, Inc. (XERS) Q4 2022 Earnings Call Transcript
Revenue
$33.14M*
▲ 54.7% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Xeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Call Transcript
Revenue
$29.73M
▲ 168.8% YoY Diluted EPS
$-0.16
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Xeris Biopharma Holdings, Inc. (XERS) Q2 2022 Earnings Call Transcript
Revenue
$25.31M
▲ 184.1% YoY Diluted EPS
$-0.19
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Xeris Biopharma Holdings, Inc. (XERS) Q1 2022 Earnings Call Transcript
Revenue
$22.07M
▲ 169.3% YoY Diluted EPS
$-0.25
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Xeris Biopharma Holdings, Inc. (XERS) Q4 2021 Earnings Call Transcript
Revenue
$21.43M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Xeris Biopharma Holdings, Inc. (XERS) Q3 2021 Earnings Call Transcript
Revenue
$11.06M
▲ 17.6% YoY Diluted EPS
$-0.39
Gross margin
70.9%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Xeris Biopharma Holdings, Inc. (XERS) Q2 2021 Earnings Call Transcript
Revenue
$8.91M
Diluted EPS
$-0.41
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Xeris Biopharma Holdings, Inc. (XERS) Q1 2021 Earnings Call Transcript
Revenue
$8.20M
Diluted EPS
$-0.30
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Xeris Biopharma Holdings, Inc. (XERS) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Xeris Biopharma Holdings, Inc. (XERS) Q3 2020 Earnings Call Transcript
Revenue
$9.40M
Gross margin
70.4%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Xeris Biopharma Holdings, Inc. (XERS) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Xeris Biopharma Holdings, Inc. (XERS) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 webcasts